KR102564672B1 - Composition for Anti-obesity Using an Extract of Sterculia lanceolata - Google Patents

Abstract

The present invention inhibits the differentiation of 3T3-L1, a mouse preadipocyte, into adipocytes in a concentration-dependent manner, and inhibits the expression of PPARγ, aP2, Fas, resistin, ADD1/SREBP1c, and adiponectin, which are factors related to adipocyte differentiation. Disclosed is an anti-obesity composition using a Steculia lanceolata extract having an activity to

Description

Composition for Anti-obesity Using an Extract of Sterculia lanceolata

The present invention relates to an anti-obesity composition using an extract of Steculia lanceolata .

Obesity is an increase in the number and size of fat cells due to excessive accumulation of body fat due to an imbalance between energy intake and consumption (Cell.104:531-543 2001), and body energy is transferred to fat cells in the form of triglycerides. When the stored energy source is exhausted, the stored fat is decomposed into free fatty acids and glycerol to be used as an energy source, but excessive intake of energy promotes the differentiation of fat cells and increases the amount of stored fat in the body, which is a direct cause of obesity. (Metabolism. 30: 425-427 1981; Biochem J. 1;435(3):723-32 2011).

Obesity acts as a risk factor that increases the incidence of various diseases as well as changes in body shape due to fat accumulation in the internal organs and abdomen (Korean J. Pediatr.48:126-137. 2005). Excessive accumulation of visceral fat causes problems with sugar metabolism in the body, and symptoms such as abnormal secretion of hormones and abnormal secretion of cytokines occur. The increase in triglyceride and LDL-cholesterol, and the decrease in HDL-cholesterol due to obesity, lead to abnormal fat metabolism in the body, decrease the insulin receptor present in the tissue, and also reduce insulin sensitivity, inhibiting the transport of glucose into cells. It can also cause high blood sugar and diabetes. Obesity is also known to be closely related to the occurrence of metabolic diseases such as hyperlipidemia, cardiovascular disease, cancer, respiratory disorders, stroke, and osteoarthritis (Med. Int. 22 385-388 1994; Ann. Intern. Med 103:1024-1029 1985).

Adipocytes are produced by differentiation from pre-adipocytes. During differentiation of these adipocytes, triglyceride accumulation occurs and expression of adipocyte-specific proteins (aP2, FAS, GLUT4, LPL, leptin) is induced, which results in PPARγ (peroxisome) proliferator-activated receptor γ), C/EBP family (CCAAT/enhancer binding proteins; C/EBRα, C/EBRβ and C/EBRδ), ADD1/SREBP1c (adipocyte determination differentiation factor 1)/(sterol regulatory element binding protein 1c) Transcription factors called adipocytes or adipokines are known to play a pivotal role (Genes De 2000, 14(11) 1293~1307) (Physiol Rev 1998, 78(3):783~809 ; Annu Rev Biochem 2008, 77:289-312; Genes Dev 1996, 10:1096-1107).

3T3-L1, an adipose adipocyte, was first isolated from 3T3 cells by Green and Meuth (Cell. 3(2):127-33. 1974), and its biological properties and the property of differentiating into adipocytes under appropriate culture conditions were revealed. It is widely used to conduct research on the differentiation process of adipocytes and the decomposition of accumulated fat. 3T3-L1 cells, which are pre-adipocytes, differentiate into mature adipocytes and accumulate intracellular triglycerides by increasing the expression of related genes and the activity of related enzymes ( J Nutr 130: 3116S-3121S, 2000; J Nutr 130: 3122S-3126S, 2000). For research on the development of functional materials, a method of searching for materials that suppress the differentiation process or promote lipolysis using 3T3-L1 cells with the aim of inhibiting excessive accumulation of neutral fat in adipose tissue is widely used (Biotechnology and Bioprocess Engineering 20 (1):157-167, 2015; Prev Nutr Food Sci (17):1-7, 2012: J Antibiot 58(10): 634-39, 2005).

Existing anti-obesity drugs such as orlistat and sibutramine are known to have serious side effects such as vomiting, constipation, gastrointestinal disorders, and cardiovascular diseases (Int J Obes Relat Metab Disord. Jul; 25(7)). : 1095-9.2001; Obes Res. 8(6):431-7.2000; Lancet. 6;369(9555):71-7.2007; Front Physiol. Efforts to develop effective and safe materials are ongoing. Retinol, vitamin E, vitamin U, Japanese pepper extract, etc. have been reported as substances that inhibit the differentiation of fat cells (Mol Cell Biol. 16:15671575. 1996;Ann Dermatol. Feb;24(1):39- 44 2012; J Nutr. 139(1):51-7 2009; Ann Dermatol. 24(1):39-44 2012) Research on the development of natural anti-obesity drugs that can be safely and continuously consumed is being actively conducted.

The present invention discloses the anti-obesity activity of Steculia lanceolata extract.

An object of the present invention is to provide an anti-obesity composition using Steculia lanceolata extract.

Other objects or specific objects of the present invention will be presented below.

As confirmed in the following Examples and Experimental Examples, the present invention suppresses the differentiation of 3T3-L1, a mouse preadipocyte, into adipocytes in a concentration-dependent manner, and also inhibits the differentiation of adipocytes-related factors It was completed by confirming that the expression of PPARγ, aP2, Fas, resistin, ADD1/SREBP1c, and adiponectin was inhibited.

Considering the above-described experimental results, the anti-obesity composition of the present invention is characterized in that it contains Steculia lanceolata extract as an active ingredient.

In the present specification, "Steculia lanceolata extract" refers to Steculia lanceolata leaves, stems, aerial parts, rhizomes, roots, underground parts, or mixtures thereof to be extracted in water, lower alcohols having 1 to 4 carbon atoms (methanol, ethanol, butanol, etc.), methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol , an extract obtained by leaching using propylene glycol or a mixed solvent thereof, an extract obtained using a supercritical extraction solvent such as carbon dioxide or pentane, or a fraction obtained by fractionating the extract, and the extraction method is the polarity of the active substance, extraction Arbitrary methods such as cooling, reflux, heating, ultrasonic radiation, and supercritical extraction may be applied in consideration of the degree and preservation degree. In the case of the fractionated extract, after suspending the extract in a specific solvent, the fraction obtained by mixing and standing with a solvent of different polarity, and the crude extract are adsorbed on a column filled with silica gel, etc., and then a hydrophobic solvent, a hydrophilic solvent, or a mixed solvent thereof It is meant to include fractions obtained as a mobile phase. In addition, the meaning of the extract includes a concentrated liquid extract or solid extract from which the extraction solvent is removed by lyophilization, vacuum drying, hot air drying, spray drying, or the like. Preferably, it refers to an extract obtained by using water, ethanol or a mixed solvent thereof as an extraction solvent, and more preferably an extract obtained by using a mixed solvent of water and ethanol alcohol as an extraction solvent.

In addition, in the present specification, "active ingredient" means a component that exhibits the desired activity alone or can exhibit activity in combination with a carrier having no activity itself.

Also, in the present specification, "anti-obesity" means a decrease in body fat, inhibition of body fat accumulation, and/or a decrease in body weight. Therefore, it means to include prevention of obesity and treatment of obesity, and further includes reducing body weight/body fat for beauty or health purposes (aka diet purposes) although weight is not classified as obesity or overweight.

In addition, in the present specification, the "obesity" refers to a state in which adipose tissue is abnormally increased, whether it is obesity caused by genetic factors or obesity caused by environmental factors, and according to the classification of body mass index (BMI), high This includes obesity (BMI greater than 30.0), obesity (BMI between 25 and 30), and overweight (BMI between 23 and 25).

The anti-obesity composition of the present invention may be included in any amount (effective amount) according to use, formulation, blending purpose, etc., as long as the active ingredient can exhibit anti-obesity activity. A typical effective amount is based on the total weight of the composition It will be determined within the range of 0.001% by weight to 20.0% by weight when Here, "effective amount" means that when the composition of the present invention is administered to a mammal, preferably a human, to which it is applied, during the administration period according to the advice of medical experts, the intended functional and pharmacological effects such as anti-obesity effect can be exhibited, It refers to the amount of the active ingredient included in the composition of the present invention. Such an effective amount can be determined empirically within the ordinary skill of the skilled artisan.

In addition to the active ingredients, the anti-obesity composition of the present invention has already been proven safe in the art in order to enhance the convenience of intake or intake through the addition of similar activities such as blood pressure control activity or to increase or reinforce the anti-obesity effect. It may further include any compound or natural extract known to have that activity. These compounds or extracts include compounds or extracts, pharmaceuticals listed in compendials such as pharmacopoeia of each country ("Korean Pharmacopoeia" in Korea) and health functional food codes of each country (in Korea, it is "standards and specifications for health functional foods", a notice of the Ministry of Food and Drug Safety). The laws of each country regulating the manufacture and sale of compounds or extracts and health functional foods that have been licensed under each country's laws ("Pharmaceutical Affairs Act" in Korea) governing the manufacture and sale of health functional foods ("Health Functional Foods Act" in Korea) ”), compounds or extracts whose functionality has been recognized are included.

For example, Garcinia cambogia peel extract, conjugated linolenic acid (free fatty acid), conjugated linolenic acid (triglyceride), green tea extract, chitosan, Lactobacillus gasseri, whose functionality has been recognized for 'body fat reduction' according to the "Health Functional Food Act" of Korea Complex such as BNR17 ( Lactobacillus gasseri BNR17), L-carnitine tartrate, green mate extract, green coffee bean extract, sesame leaf extract, soybean embryo extract, rhododendron leaf alcohol extract powder, lactoferrin (milk purified protein), lemon balm extract mixture powder , Mate hot water extract, seaweed and other complex extracts (Xanthigen), fermented vinegar pomegranate complex, Puer tea extract, Seomoktae (swine pea) peptide complex, vegetable oil diglyceride, wild mango seed extract, medium chain fatty acid (MCFA)-containing oil, Coleus forskoli extract, chitooligosaccharide, fingerroot extract powder, complex extracts such as hibiscus, etc., L-glutamic acid-derived GABA-containing powder whose functionality has been recognized as 'blood pressure control', katsuobushi oligopeptide, Natto bacteria cultured powder, Seomoktae Soybean) Peptide complex, salmon peptide, olive leaf extract, sardine peptide, casein hydrolysate, coenzyme Q10, grape seed enzyme decomposition extract powder, Haitai oligopeptide, etc., DHA concentrated oil and globin hydrolyzate recognized as 'improving blood triglycerides' , indigestible maltodextrin, bamboo leaf extract, vegetable oil diglyceride, sardine-refined fish oil, refined squid oil, etc., L-arabinose whose functionality has been recognized as 'glycemic control', nopal extract, cinnamon extract powder, guava leaf extract, ovary Hwaseong maltodextrin, freeze-dried silkworm powder, marijuana extract, banaba leaf extract, leaf extract, etc., fermentation-produced amino acid complex whose functionality has been recognized as 'fatigue improvement', hovenia pedunculus extract, rhodiola extract, etc., functional as 'anti-stress' These recognized L-theanine, ashwagandha extract, hydrolysate of milk protein, and extract of the leaves of the plant will correspond to these compounds or extracts.

The anti-obesity composition of the present invention can be understood as a food composition in a specific aspect.

The food composition of the present invention can be prepared in any form, for example, beverages such as tea, juice, carbonated beverages, and ionic beverages, processed oils such as milk and yogurt, chewing gum, rice cakes, traditional Korean snacks, bread, snacks, noodles, etc. It can be manufactured into health functional food preparations such as foods, tablets, capsules, pills, granules, liquid, powder, flakes, pastes, syrups, gels, jellies, and bars.

In addition, the food composition of the present invention may take any product classification as long as it conforms to the enforcement regulations at the time of manufacture and distribution in legal and functional classification. For example, health functional food according to the Korean 「Health Functional Food Act」, or snacks, legumes, teas, beverages according to each food type according to the Food Code (MFDS notification 「Food Standards and Specifications」) of the Korea 「Food Sanitation Act」 , special purpose foods, etc.

The food composition of the present invention may include food additives in addition to the active ingredient. Food additives may generally be understood as substances that are added to, mixed with, or infiltrated into food in manufacturing, processing, or preserving food. Since food is consumed daily and for a long period of time, its safety must be guaranteed. According to the Food Additives Code under the laws of each country governing the manufacture and distribution of food (in Korea, it is the 「Food Sanitation Act」), safety-guaranteed food additives are limitedly regulated in terms of ingredients or functions. In the Korean Food Additives Codex (MFDS notification 「Standards and Specifications for Food Additives」), food additives are classified into chemical synthetic products, natural additives and mixed preparations in terms of ingredients and are regulated. It is divided into additives, preservatives, emulsifiers, acidulants, and thickeners.

Sweeteners are used to impart appropriate sweetness to foods, and both natural and synthetic sweeteners can be used in the food composition of the present invention. Preferably, a natural sweetener is used, and examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.

Flavors are used to improve taste or aroma, and both natural and synthetic flavors may be used. Preferably, it is the case of using a natural one. In case of using natural ones, in addition to flavor, the purpose of enhancing nutrition can be combined. As a natural flavoring agent, it may be obtained from apples, lemons, tangerines, grapes, strawberries, peaches, etc., or obtained from green tea leaves, roundworms, bamboo leaves, cinnamon, chrysanthemum leaves, jasmine, and the like. In addition, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, ginkgo, etc. can be used. Natural flavors can be liquid concentrates or solid extracts. In some cases, synthetic flavors may be used, and as synthetic flavors, esters, alcohols, aldehydes, terpenes, and the like may be used.

As preservatives, calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), etc. may be used, and as emulsifiers, acacia gum, carboxymethylcellulose, xanthan gum, pectin etc. may be used, and as an acidulant, acidulic acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, and the like may be used. Acidulants may be added to the food composition to have an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to improving taste. As the thickening agent, a suspending agent, a sedimentation agent, a gel forming agent, a swelling agent, and the like may be used.

In addition to the food additives described above, the food composition of the present invention may include physiologically active substances or minerals that are known in the art and whose stability is guaranteed as food additives for the purpose of supplementing and reinforcing functionality and nutrition.

Examples of such physiologically active substances include catechins contained in green tea, vitamins such as vitamin B1, vitamin C, vitamin E, and vitamin B12, tocopherol, dibenzoylthiamine, and the like. Examples of minerals include calcium preparations such as calcium citrate and magnesium stearate. magnesium preparations such as the like, iron preparations such as iron citrate, chromium chloride, potassium iodine, selenium, germanium, vanadium, zinc, and the like.

The food composition of the present invention may include the above-mentioned food additives in an appropriate amount to achieve the purpose of addition according to the type of product.

Regarding other food additives that may be included in the food composition of the present invention, reference may be made to national food codes or food additive codes.

The composition of the present invention can be understood as a pharmaceutical composition in another specific aspect.

The pharmaceutical composition of the present invention may be formulated into an oral formulation or a parenteral formulation according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredient. The route of administration herein may be any appropriate route including topical route, oral route, intravenous route, intramuscular route, and direct absorption through mucosal tissue, and two or more routes may be used in combination. An example of a combination of two or more routes is a case in which two or more formulations of drugs are combined according to the route of administration, for example, one drug is firstly administered intravenously and the other drug is secondly administered through a topical route.

Pharmaceutically acceptable carriers are well known in the art depending on the route of administration or dosage form, and specifically, reference may be made to the pharmacopoeia of each country including the "Korean Pharmacopoeia".

When the pharmaceutical composition of the present invention is prepared as an oral dosage form, powder, granule, tablet, pill, dragee, capsule, liquid, gel, syrup, suspension, wafer according to a method known in the art together with a suitable carrier. It can be prepared in formulations such as Examples of suitable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, and xylitol, starches such as corn starch, potato starch, and wheat starch, cellulose, methylcellulose, ethylcellulose, sodium carboxymethylcellulose, Celluloses such as hydroxypropylmethylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable oil, ethanol, Serol etc. are mentioned. In the case of formulation, appropriate binders, lubricants, disintegrants, coloring agents, diluents, etc. may be included as needed. Suitable binders include starch, magnesium aluminum silicate, starch ferrite, gelatin, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, glucose, corn sweetener, sodium alginate, polyethylene glycol, wax, and the like, and oleic acid as a lubricant sodium, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, magnesium salts and calcium salts thereof, polyethylene glycol, etc., and disintegrants include starch, methyl cellulose , agar, bentonite, xanthan gum, starch, alginic acid or its sodium salt, and the like. Examples of the diluent include lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, and glycine.

When the pharmaceutical composition of the present invention is prepared as a parenteral formulation, it may be formulated in the form of an injection, transdermal administration, nasal inhalation, and suppository along with a suitable carrier according to a method known in the art. When formulated as an injection, an aqueous isotonic solution or suspension may be used as a suitable carrier, and specifically, an isotonic solution such as phosphate buffered saline (PBS) containing triethanolamine, sterile water for injection, or 5% dextrose may be used. . When formulated as a transdermal formulation, it may be formulated in the form of ointments, creams, lotions, gels, external solutions, pastas, liniments, air rolls, and the like. In the case of nasal inhalation, it can be formulated in the form of an aerosol spray using a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc., and when formulated as a suppository, the carrier is Witepsol ( witepsol), tween 61, polyethylene glycols, cacao fat, laurin fat, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, sorbitan fatty acid esters, and the like can be used.

Regarding the specific formulation of the pharmaceutical composition, it is known in the art, and for example, reference may be made to Remington's Pharmaceutical Sciences (19th ed., 1995) and the like. These documents are considered as part of this specification.

The preferred dosage of the pharmaceutical composition of the present invention is in the range of 0.001 mg/kg to 10 g/kg per day, preferably 0.001 mg/kg to 1 g, depending on the patient's condition, weight, sex, age, severity of the patient, and route of administration. /kg range. Administration can be done once a day or divided into several times. These dosages should not be construed as limiting the scope of the present invention in any respect.

As described above, according to the present invention, it is possible to provide an anti-obesity composition using the Steculia lanceolata extract. The anti-obesity composition of the present invention can be commercialized as functional food, medicine, and the like.

1 is a result showing that the Steculia lanceolata extract inhibits the differentiation of 3T3-L1, which is a mouse preadipocyte, into adipocytes.
2 to 4 are results showing that the Steculia lanceolata extract inhibits the expression of adipocyte differentiation-related factors.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these Examples and Experimental Examples.

< Example > Preparation of Steculia lanceolata extract

Steculia lanceolata (extracted part, branch) is dried After adding 70% ethanol to the powder and extracting at room temperature for 24 hours, the mixture was filtered with a filter paper (Whatman No 2), and the filtrate was concentrated under reduced pressure and lyophilized to obtain a solid extract (NIBR No. 907).

< Experimental example > Obesity improvement activity test of Steculia lanceolata extract

<Experimental Example 1> Adipocyte differentiation inhibitory activity test

Mouse preadipocytes, 3T3-L1 (Zenbio SP-L1-F), were cultured in 3T3-L1 Preadipocyte Medium (Zenbio PM-1-L1) medium at 37°C and 5% CO ₂ . 3T3-L1 preadipocytes were dispensed in a 24 well plate at a cell number of 5×10 ⁴ cells/well, and then maintained for 2 days at 100% confluency. Adipocyte differentiation was induced for 2 days with 3T3-L1 Differentiation Medium (Zenbio DM-2-L1) medium containing MDI (Isobutylmethylxanthine, dexamethasone, insulin), and after 48 hours of culture, every 2 days for 6 days. It was cultured while replacing the medium with 3T3-L1 Adipocyte Medium (Zenbio AM-1-L1). During the induction of adipocyte differentiation, samples were treated with each culture medium at each concentration, and the degree of adipocyte differentiation was observed on the 8th day, when differentiation was completed. The degree of adipocyte differentiation was first confirmed through a microscope through Oil Red O staining, and the degree of adipocyte staining was measured for the amount of differentiated fat cells at 510 nm absorbance. The results were calculated through repeated experiments three times for each concentration.

The results are shown in Figure 1. Referring to Figure 1, it can be seen that the Steculia lanceolata extract has a concentration-dependent activity of inhibiting the differentiation of preadipocytes into adipocytes and of inhibiting fat accumulation.

<Experimental Example 2> Evaluation of expression inhibition activity at the protein level of adipocyte differentiation-related factors

After treating the sample in 3T3-L1 cells as in the induction of adipocyte differentiation, the cells were washed twice with PBS and RIPA buffer (Sigma, St. Louis, MO) containing protease inhibitors (1mM PMSF, 2mM Na3VO4, 50mM NaF). ) was used to lyse the cells. Proteins were extracted and quantified by centrifugation at 13,000 rpm for 30 minutes, and electrophoresed using an 8% SDS-PAGE gel. Electrophoresed proteins were transferred to a membrane and then blocked with TBST containing 5% skim milk. As primary antibodies, anti-PPARγ and anti-C/EBPa (Cell signaling technology) were used, and as secondary antibodies, HRP-conjugated anti-rabbit was used. The expression level of each protein was analyzed using SuperSignal®west pico chemiluminescent substrate (Thermo Scientific, Rockford, IL, USA) and Amersharm image 600 (GE Healthcare Life Sciences, Chicago, Illinois, USA). was evaluated by comparing with the expression level of β-actin.

Results are shown in FIG. 2 . It can be seen that the expression of PPARγ and C/EBPα decreased in proportion to the treatment concentration of Steculia lanceolata extract.

<Experimental Example 3> Evaluation of expression inhibition activity at the gene level of adipocyte differentiation-related factors

Adipocytes were differentiated for 8 days in the same way as the method for measuring the activity of inhibiting adipocyte differentiation, and the expression levels of PPARγ, C/EBRa, aP2, Fas, resistin, ADD1/SREBP1c, and adiponectin were confirmed by real-time PCR. Total RNA was isolated from 3T3-L1 cells differentiated for 8 days using TRIzol reagent (Invitrogen, CA, USA). For the extracted RNA, cDNA was synthesized using the SuperScript®III First-Strand Synthesis System, and then real-time PCR was performed using SYBR green (Takara) and the primers shown in [Table 1] below, and glyceraldehyde-3-phosphate was used as a control gene. dehydrogenase (GAPDH) was used. Fluorescence signals were quantified using the Bio-Rad MyiQ program.

primer Gene name Forward primer Reverse primer GAPDH 5’-GTATGACTCCACTCACGGCAAA-3’ 5'-GGTCTCGCTCCTGGAAGATG-3' PPARγ 5'-CGCTGATGCACTGCCTATGA-3' 5'-AGAGGTCCACAGAGCTGATTCC-3' C/EBPα 5'-AGGTGCTGGAGTTGACCAGT-3' 5'-CAGCCTAGAGATCCAGCGAC-3' aP2 5’-CATGGCCAAGCCCAACAT-3’ 5’-CGCCCAGTTTTGAAGGAAATC-3’ Fas 5’-CTGAGATCCCAGCACTTCTTGA-3’ 5’-GCCTCCGAAGCCAAATGAG-3’ resistin 5'-TCAACTCCCTGTTTCCAAATGC-3' 5'-TCTTCACGAATGTCCCACGA-3' ADD1/SREBP1c 5'-CAAACTGCCCATCCACCGAC-3' 5'-TGCCTCCTCCACTGCCACAA-3' adiponectin 5'-AGCCTGGAGAAGCCGCTTAT-3' 5'-TTGCAGTAGAACTTGCCAGTGC-3'

Results are shown in Figures 3 and 4. The expression of PPARγ, aP2, Fas, resistin, ADD1/SREBP1c, and adiponectin decreased in proportion to the treatment concentration of Steculia lanceolata extract.

Claims (4)

An anti-obesity food composition containing water, ethanol or a mixed solvent extract of Steculia lanceolata as an active ingredient.
According to claim 1,
The Steculia lanceolata extract is an anti-obesity food composition, characterized in that obtained by extracting the Steculia lanceolata branches.
An anti-obesity pharmaceutical composition containing water, ethanol or a mixed solvent extract of Steculia lanceolata as an active ingredient.
According to claim 3,
The Steculia lanceolata extract is an anti-obesity pharmaceutical composition, characterized in that obtained by extracting Steculia lanceolata branches.